Drug Interaction Report

MONITOR CLOSELY: The concomitant use of ticagrelor with other platelet inhibitors, anticoagulants, thrombolytic agents, or nonsteroidal anti-inflammatory drugs may increase the risk of bleeding, including severe and sometimes fatal hemorrhage.

MANAGEMENT: Caution is advised when these drugs are used concomitantly with ticagrelor or within 24 hours of ticagrelor dosing. Close clinical and laboratory observation for hemorrhagic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their doctor, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding, or bruising, red or brown urine, or red or black stools.

The recommended maximum number of medicines in the 'ADP receptor antagonists' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'ADP receptor antagonists' category:

• Kengreal (cangrelor)
• ticagrelor

Note: In certain circumstances, the benefits of taking this combination of drugs may outweigh any risks. Always consult your healthcare provider before making changes to your medications or dosage.